BPC-157 ClinicalTrials.gov Registry: NCT07437547 Status & Full Trial History
ClinicalTrials.gov lists just 2 BPC-157 trials: the recruiting NCT07437547 Phase 2 hamstring study and a 2015 Phase 1 pilot with no results ever posted.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
BPC-157's ClinicalTrials.gov footprint is smaller than its research profile suggests: a direct registry search turns up exactly two studies, including the actively recruiting Phase 2 trial NCT07437547, and researchers searching for a fuller picture of the compound's human-trial history often can't find both records in one place. This review lays out every BPC-157 entry currently listed on ClinicalTrials.gov, what each one actually studied, and what the registry gap between BPC-157's decades of preclinical publication and its thin human-trial record means for researchers tracking the compound through the July 2026 FDA PCAC review cycle.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: ClinicalTrials.gov currently lists two BPC-157 study records: NCT07437547, an actively recruiting Phase 2 randomized trial for acute hamstring strain (Hudson Biotech, 120-participant target), and NCT02637284, a completed-but-unresulted 2015 Phase 1 pharmacokinetics pilot in Mexico that studied an oral BPC-157 tablet formulation called Bepecin.
TL;DR:
- Two ClinicalTrials.gov records exist for BPC-157: one active Phase 2 trial and one closed Phase 1 pilot.
- NCT07437547 is the only trial testing injectable BPC-157 in a controlled human population; it is currently recruiting toward a February 2027 primary completion.
- NCT02637284 (2015, Tijuana, Mexico) tested oral BPC-157 tablets for safety and pharmacokinetics in 42 healthy volunteers; its status is listed as unknown and no results were ever posted.
- BPC-157 has no FDA approval and remains under active FDA PCAC review for its 503A compounding status, with a decision expected after the July 23–24, 2026 hearing.
- Compared to related tissue-repair peptides like TB-500, which has no ClinicalTrials.gov listing at all, BPC-157's two-trial registry record is still the deeper of the two.
What the registry search shows
A direct ClinicalTrials.gov search for "BPC-157" returns two study records, not one. Most site content and casual research summaries reference only the newer, currently recruiting NCT07437547 hamstring trial, which is a reasonable default since it's the only trial testing the compound in the route and indication most research protocols use. But an older record, NCT02637284, also appears in the federal registry and predates it by roughly a decade.
NCT02637284 was registered in December 2015 by the sponsor PharmaCotherapia d.o.o., titled "Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source." It was a randomized, placebo-controlled, quadruple-masked pilot conducted at Hospital Ángeles in Tijuana, Mexico, testing oral tablets (branded Bepecin) containing 1 mg of BPC-157 in single-ascending-dose and 14-day repeated-dose cohorts across 42 healthy volunteers aged 18–35. Primary outcome measures were adverse event monitoring; secondary measures targeted standard pharmacokinetic parameters (Cmax, Tmax, AUC, half-life). The study's last update was posted in December 2015, its status field currently reads "Unknown" on ClinicalTrials.gov, and no results were ever submitted to the registry — a common outcome for small international pilot studies that are not followed by formal publication.
By contrast, NCT07437547 is a randomized, double-blind, placebo-controlled Phase 2 trial sponsored by Hudson Biotech, currently recruiting 120 participants at Peking University Shenzhen Hospital to evaluate subcutaneous BPC-157 injections against placebo for accelerating repair of MRI-confirmed grade II hamstring strain. It has co-primary endpoints of time to return to unrestricted sport and change in MRI-assessed injury volume at day 14, with a primary completion estimate of February 2027. Full trial design details, eligibility criteria, and endpoint definitions are covered in the standalone NCT07437547 trial summary.
How BPC-157's registry record compares
| Trial | NCT02637284 | NCT07437547 |
|---|---|---|
| Phase | Phase 1 | Phase 2 |
| Status | Unknown (last updated Dec 2015) | Recruiting |
| Population | 42 healthy volunteers | 120 participants with acute hamstring strain |
| Route | Oral tablet (Bepecin/PCO-02) | Subcutaneous injection |
| Primary endpoint | Adverse events | Return to sport; MRI injury volume change |
| Sponsor | PharmaCotherapia d.o.o. | Hudson Biotech |
| Results posted | No | Not yet (ongoing) |
The gap between these two trials is nearly a decade, and they test different formulations entirely — an oral tablet product versus an injectable research compound — which limits how directly one informs interpretation of the other. Researchers citing "the BPC-157 clinical trial" in singular terms are almost always referring to NCT07437547, since it is the only active, injectable-route study and the one most relevant to the compound's current preclinical research literature summarized on the BPC-157 library profile.
For context, this two-trial registry record is still comparatively substantial among tissue-repair peptides under current FDA review. TB-500, BPC-157's frequent research comparator, has no ClinicalTrials.gov listing at all despite a similarly large preclinical literature base — a pattern also seen with KPV, another compound under review in the same July 2026 PCAC docket.
What this means for research access
Neither BPC-157 trial has produced posted results, so no human efficacy data currently exists in the ClinicalTrials.gov system for either the oral or injectable formulation. That leaves BPC-157's evidence base for research purposes resting almost entirely on the preclinical literature — angiogenesis, collagen synthesis, and nitric oxide pathway modulation data from rodent and cell-culture models — while NCT07437547 remains the only registered pathway toward controlled human data.
This registry status is directly relevant to the FDA's ongoing Pharmacy Compounding Advisory Committee review. As detailed in the BPC-157 503A status analysis, the committee's evaluation weighs available clinical and safety data when recommending Category 1 or Category 2 bulk drug substance status. A thin, unresulted trial record — two studies, neither with posted outcomes — is a materially different evidence picture than a compound with completed Phase 2 or Phase 3 data, and it is one of the factors likely to inform the committee's July 23–24, 2026 recommendation.
Researchers monitoring whether NCT07437547 posts interim data, whether new BPC-157 trials are filed, or whether other PCAC-docket compounds see similar registry activity can track new and updated filings directly using the ClinicalTrials.gov trial tracker tool, which surfaces newly registered studies as they appear in the federal registry.
Timeline and what's next
NCT07437547's primary completion is estimated for February 2027, meaning no interim efficacy readout is expected before then absent a planned interim analysis disclosed in the protocol. NCT02637284 has shown no registry activity since December 2015 and should be treated as closed with an unknown final outcome rather than as an ongoing study.
The more immediate date on the calendar is the FDA PCAC hearing on July 23–24, 2026, where BPC-157's compounding status will be formally discussed alongside six other peptides. That hearing does not depend on NCT07437547 reaching completion — the committee will evaluate the existing (currently incomplete) trial and safety record as it stands. Researchers should expect the registry picture described here to be the operative one through the hearing date, with any updates most likely to come from a status change on NCT07437547 (e.g., a shift from "Recruiting" to "Active, not recruiting") or a new trial filing rather than from NCT02637284.
External sources
- PMID 41898733 — "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management" (2026).
- PMID 41476424 — "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians" (2026).
- ClinicalTrials.gov study record NCT07437547 — clinicaltrials.gov/study/NCT07437547.
- ClinicalTrials.gov study record NCT02637284 — clinicaltrials.gov/study/NCT02637284.
Frequently asked questions
Q: How many clinical trials for BPC-157 are listed on ClinicalTrials.gov?
A: Two. NCT07437547 is an actively recruiting Phase 2 trial testing injectable BPC-157 for acute hamstring strain, and NCT02637284 is a completed-but-unresulted 2015 Phase 1 pilot that tested an oral BPC-157 tablet formulation in healthy volunteers.
Q: Is NCT07437547 the first human trial of BPC-157?
A: No, though it is the first controlled trial of the injectable route in a musculoskeletal injury indication. NCT02637284, registered in 2015, predates it and tested an oral tablet formulation, but that earlier study's status is listed as unknown with no results ever posted.
Q: Why hasn't NCT02637284 posted any results?
A: ClinicalTrials.gov shows no update to the record since December 2015, and its status field reads "Unknown." This is a common outcome for small international pilot studies that are not followed by a formal results submission or publication, and the registry provides no further explanation.
Q: Does BPC-157 have more or fewer registered trials than similar research peptides?
A: More than some. TB-500, BPC-157's frequent research comparator, has no ClinicalTrials.gov listing at all, as does KPV. BPC-157's two-trial record, while still thin relative to an FDA-approved drug, is comparatively more developed within its peer group of tissue-repair peptides under current regulatory review.
Q: How can researchers track new BPC-157 trial filings?
A: ClinicalTrials.gov updates continuously as sponsors submit new studies. Researchers can search the registry directly or use the site's trial tracker tool, which surfaces newly registered studies relevant to compounds covered in this research library.
See also:
- NCT07437547 BPC-157 Phase 2 Trial: Status, Endpoints & Research Summary — full trial design, eligibility criteria, and endpoint details for the active Phase 2 study.
- BPC-157 503A Status: What a Category 1 Designation Means for Research Access — how the FDA PCAC review connects to BPC-157's trial and safety record.
- Selank ClinicalTrials.gov Registry: Trial Status and Research Access — the same registry-gap pattern in a peptide with zero U.S. trial listings.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.